

Clinical Updates in Breast Cancer from Madrid

Neoadjuvant ICI for High-Risk, ER+/HER2- Breast Cancer

References

Tweet 2 References:

Cardoso F, McArthur HL, Schmid P, et al. KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer. Abstract presented at: 2023 ESMO Congress 2023; October 20, 2023; Madrid, Spain. Abstract LBA21.

Additional References:

Cardoso F, McArthur HL, Schmid P, et al. KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer. Abstract presented at: 2023 ESMO Congress 2023; October 20, 2023; Madrid, Spain. Abstract LBA21.

Loi S, Curigliano G, Salgado RF, et al. A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC). Abstract presented at: 2023 ESMO Congress 2023; October 20, 2023; Madrid, Spain. Abstract LBA20.

Johnston S. Invited Discussant LBA20 and LBA21. Presentation at: 2023 ESMO Congress 2023; October 20, 2023; Madrid, Spain.

Torrì R, Marrazzo E, Agostinetti E, et al. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what? *Crit Rev Oncol/Hematol*. 2021;160:103280. doi:10.1016/j.critrevonc.2021.103280

Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. *N Engl J Med*. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651

Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. *J Clin Oncol*. 2017;35(15_suppl):506. doi:10.1200/JCO.2017.35.15_suppl.506

Glossary

AE, adverse event
BrCa, breast cancer
CM, CheckMate
CME, continuing medical education
CT, chemotherapy
DFS, disease-free survival
EFS, event-free survival
ER+, estrogen receptor positive
esBrCa, early-stage breast cancer
ESMO, European Society for Medical Oncology
HER2+, human epidermal growth factor receptor 2
ICI, immune checkpoint inhibitor
IDC, invasive ductal carcinoma
KN, KEYNOTE
NAC, neoadjuvant chemotherapy
neoadj, neoadjuvant
pCR, pathological complete response
pembro, pembrolizumab
pop, population
QW, every
TRAE, treatment-related AE
w/, with